Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$113.18

1.8 (1.62%)

13:11
11/17/19
11/17
13:11
11/17/19
13:11

Analysis shows Jardiance decreased risk of hospitalization for heart failure

A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty, EMPRISE, real-world study on effectiveness shows that Jardiance was associated with a decreased risk of hospitalization for heart failure and a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors and GLP-1 receptor agonists. The interim analysis included 190,000 adults in the U.S. with type 2 diabetes with and without cardiovascular disease. The results were shared on behalf of Boehringer Ingelheim and Eli Lilly and Company (LLY) at the American Heart Association Scientific Sessions 2019 in Philadelphia.

  • 30

    Jan

LLY Eli Lilly
$113.18

1.8 (1.62%)

09/09/19
PIPR
09/09/19
NO CHANGE
Target $85
PIPR
Neutral
Lilly's 'impressive update' raised bar higher for Blueprint, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said he thinks Eli Lilly (LLY) issued an "impressive update" on selpercatinib at the World Lung meeting, raising the bar for Blueprint Medicines' (BPMC) pralsetinib "meaningfully higher." While selpercatinib's "best-in-class" ORR was maintained, initial durability data could be upwards of 50% better than that of pralsetinib, according to Raymond. While cautioning that his comparison is highly preliminary, Raymond said he worries that LOXO-292's superiority gap against pralsetinib "may be widening." He keeps a Neutral rating on Blueprint shares, which are down about 3% in morning trading to $75.89.
09/25/19
PIPR
09/25/19
NO CHANGE
Target $81
PIPR
Overweight
AbbVie survey supports above-consensus estimates, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on AbbVie (ABBV) shares with an $81 price target following a new rheumatologist survey by his firm's partners Spherix Global Insights. The survey indicates "robust" expectations for the company's oral JAK1 inhibitor Rinvoq, Raymond tells investors in a research note. Rheumatologists project that in six months, Rinvoq will leapfrog Eli Lilly's (LLY) Olumiant to become the second-most prescribed JAK with 5% share, says the analyst, citing the survey. He believes this supports his above-consensus Rinvoq revenue estimates.
10/16/19
BOFA
10/16/19
INITIATION
Target $133
BOFA
Buy
Eli Lilly reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of Eli Lilly with a Buy rating and $133 price target. The analyst sees the company's "high quality, differentiated growth and modest expectations for added pipeline value" as compelling.
11/06/19
LEER
11/06/19
NO CHANGE
LEER
Outperform
ArQule data for ARQ 531 'continue to look strong,' says SVB Leerink
SVB Leerink analyst Jonathan Chang said a "positive update" on the Phase 1 study of ARQ 531 in B-cell malignancies was among the abstracts published ahead of the American Society of Hematology, or ASH, annual meeting. The abstract highlights new partial responses achieved in the "short" window between the European Hematology Association update and the ASH abstract submission deadline, noted Chang, who contends that the data "continue to look strong" for the ArQule (ARQL) drug. The analyst, who also thinks that early data reported by Eli Lilly (LLY) will "intensify investor discussion on the competitive landscape for ARQ 531," still believes ArQule remains in the lead and he reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

ETFC

E-Trade

$45.37

-0.18 (-0.40%)

07:37
12/11/19
12/11
07:37
12/11/19
07:37
Hot Stocks
E-Trade reports November DARTs up 32% y/y »

E-Trade released its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 18

    Dec

  • 26

    Feb

FTV

Fortive

$73.83

-0.31 (-0.42%)

, EMR

Emerson

$74.54

-0.61 (-0.81%)

07:36
12/11/19
12/11
07:36
12/11/19
07:36
Upgrade
Fortive, Emerson, Gardner Denver rating change  »

Fortive upgraded to…

FTV

Fortive

$73.83

-0.31 (-0.42%)

EMR

Emerson

$74.54

-0.61 (-0.81%)

GDI

Gardner Denver

$33.43

-0.47 (-1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

ADBE

Adobe

$304.21

-2.78 (-0.91%)

07:36
12/11/19
12/11
07:36
12/11/19
07:36
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 23

    Jan

AAXN

Axon

$72.63

0.36 (0.50%)

07:35
12/11/19
12/11
07:35
12/11/19
07:35
Hot Stocks
Axon's Body 2 cameras selected by Corrective Services New South Wales »

Axon subsidiary Axon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSW

Seaspan

$13.76

0.31 (2.30%)

, LPI

Laredo Petroleum

$2.59

0.12 (4.86%)

07:35
12/11/19
12/11
07:35
12/11/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

SSW

Seaspan

$13.76

0.31 (2.30%)

LPI

Laredo Petroleum

$2.59

0.12 (4.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTSV

Forty Seven

$34.60

4.19 (13.78%)

07:34
12/11/19
12/11
07:34
12/11/19
07:34
Recommendations
Forty Seven analyst commentary  »

Forty Seven price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARWR

Arrowhead

$70.76

2.96 (4.37%)

07:34
12/11/19
12/11
07:34
12/11/19
07:34
Hot Stocks
Arrowhead files IND for Phase 1b study of ARO-HIF2 for treatment of ccRCC »

Arrowhead Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTEC

Intec Pharma

$0.58

0.0111 (1.95%)

, NVS

Novartis

$92.79

0.24 (0.26%)

07:33
12/11/19
12/11
07:33
12/11/19
07:33
Hot Stocks
Novartis terminates Accordion Pill development agreement with Intec Pharma »

Novartis (NVS) has…

NTEC

Intec Pharma

$0.58

0.0111 (1.95%)

NVS

Novartis

$92.79

0.24 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

AZO

AutoZone

$1,250.39

79.085 (6.75%)

07:33
12/11/19
12/11
07:33
12/11/19
07:33
Recommendations
AutoZone analyst commentary  »

AutoZone price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 18

    Dec

DBI

Designer Brands

$14.18

-2.83 (-16.64%)

07:32
12/11/19
12/11
07:32
12/11/19
07:32
Recommendations
Designer Brands analyst commentary  »

Designer Brands price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLCM

Bellicum Pharmaceuticals

$0.80

-0.009 (-1.12%)

07:32
12/11/19
12/11
07:32
12/11/19
07:32
Hot Stocks
Bellicum Pharmaceuticals licenses CaspaCIDe Safety Switch to MD Anderson »

Bellicum Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QRVO

Qorvo

07:31
12/11/19
12/11
07:31
12/11/19
07:31
Recommendations
Qorvo analyst commentary  »

Qorvo price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVGO

Broadcom

$315.10

0.61 (0.19%)

07:31
12/11/19
12/11
07:31
12/11/19
07:31
Recommendations
Broadcom analyst commentary  »

Broadcom price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

OMCL

Omnicell

$82.06

2.03 (2.54%)

07:31
12/11/19
12/11
07:31
12/11/19
07:31
Recommendations
Omnicell analyst commentary  »

Omnicell price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWW

Grainger

$323.51

-0.83 (-0.26%)

07:29
12/11/19
12/11
07:29
12/11/19
07:29
Upgrade
Grainger rating change  »

Grainger upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

PLCE

Children's Place

$70.67

0.68 (0.97%)

07:29
12/11/19
12/11
07:29
12/11/19
07:29
Hot Stocks
Children's Place down 17% to $58.20 after lowering FY19 guidance »

The company's Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

BBSI

Barrett Business

$89.45

1.85 (2.11%)

07:29
12/11/19
12/11
07:29
12/11/19
07:29
Initiation
Barrett Business initiated  »

Barrett Business…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

MA

MasterCard

$288.56

-0.48 (-0.17%)

07:28
12/11/19
12/11
07:28
12/11/19
07:28
Recommendations
MasterCard analyst commentary  »

MasterCard price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROK

Rockwell Automation

$199.78

0.89 (0.45%)

07:28
12/11/19
12/11
07:28
12/11/19
07:28
Upgrade
Rockwell Automation rating change  »

Rockwell Automation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBT

Welbilt

$16.32

-0.14 (-0.85%)

07:27
12/11/19
12/11
07:27
12/11/19
07:27
Downgrade
Welbilt rating change  »

Welbilt downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCI

Crown Castle

$134.00

-1.93 (-1.42%)

07:26
12/11/19
12/11
07:26
12/11/19
07:26
Conference/Events
Crown Castle management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

THDDY

TV Asahi

$0.00

(0.00%)

07:22
12/11/19
12/11
07:22
12/11/19
07:22
Initiation
TV Asahi initiated  »

TV Asahi initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEM

Agnico Eagle

$59.19

-0.11 (-0.19%)

07:21
12/11/19
12/11
07:21
12/11/19
07:21
Upgrade
Agnico Eagle rating change  »

Agnico Eagle upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOLD

Barrick Gold

07:21
12/11/19
12/11
07:21
12/11/19
07:21
Upgrade
Barrick Gold rating change  »

Barrick Gold upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FQVLF

First Quantum Minerals

$0.00

(0.00%)

07:21
12/11/19
12/11
07:21
12/11/19
07:21
Downgrade
First Quantum Minerals rating change  »

First Quantum Minerals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.